Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma

Timothy G. Murray, Joan M. O'Brien, Richard A. Steeves, Barbara J. Smith, Daniel M. Albert, Nicole Cicciarelli, Arnold Markoe, Dean T. Tompkins, Jolene J. Windle

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Combined modality therapy for childhood retinoblastoma holds the potential of decreasing treatment related morbidity while maintaining excellent tumor control rates. Objective: To evaluate the efficacy of external beam radiation therapy (EBRT), ferromagnetic hyperthermia (FMH), and the combination of both modalities in the control of ocular tumors in a transgenic murine model of retinoblastoma. Methods: One hundred sixty-six mouse eyes from 4-week-old animals transgenically positive for simian virus 40 large T antigen were treated with a total dose of 10, 15, 20, 30, 40, 45, or 50 Gy of EBRT in 5-Gy fractions twice daily, with 48°C or 54°C FMH for 20 minutes, or with combined EBRT at 10 or 30 Gy and 48°C or 54°C FMH for 20 minutes. Serial histologic sections, obtained 8 weeks after treatment, were examined for the presence of tumor. Results: The tumor control dose for 50% of eyes (TCD50) treated with EBRT occurred at 27.6 Gy. Ferromagnetic hyperthermia at 48°C cured 30% (6/20) of eyes, while 54°C FMH resulted in a 100% (20/20) cure rate. Combined treatment with 48°C FMH and EBRT exhibited a TCD50 at 3.3 Gy. The thermal enhancement ratio was 8.4. Ferromagnetic hyperthermia at 54°C exhibited tumor cure in all animals, but 25% of eyes were lost owing to secondary treatment complications. Conclusions: This represents the first documentation of tumor control via EBRT, ocular FMH, and a combination of these treatment modalities in this murine transgenic retinoblastoma model. The extent of treatment synergy in this model suggests that combined treatment application may allow a reduction in total ocular and periocular radiation dose while maintaining excellent local tumor control.

Original languageEnglish
Pages (from-to)1376-1381
Number of pages6
JournalArchives of Ophthalmology
Volume114
Issue number11
StatePublished - Nov 1 1996
Externally publishedYes

Fingerprint

Retinoblastoma
Fever
Radiotherapy
Neoplasms
Therapeutics
Combined Modality Therapy
Simian virus 40
Viral Tumor Antigens
Documentation
Hot Temperature
Radiation
Morbidity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Murray, T. G., O'Brien, J. M., Steeves, R. A., Smith, B. J., Albert, D. M., Cicciarelli, N., ... Windle, J. J. (1996). Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. Archives of Ophthalmology, 114(11), 1376-1381.

Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. / Murray, Timothy G.; O'Brien, Joan M.; Steeves, Richard A.; Smith, Barbara J.; Albert, Daniel M.; Cicciarelli, Nicole; Markoe, Arnold; Tompkins, Dean T.; Windle, Jolene J.

In: Archives of Ophthalmology, Vol. 114, No. 11, 01.11.1996, p. 1376-1381.

Research output: Contribution to journalArticle

Murray, TG, O'Brien, JM, Steeves, RA, Smith, BJ, Albert, DM, Cicciarelli, N, Markoe, A, Tompkins, DT & Windle, JJ 1996, 'Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma', Archives of Ophthalmology, vol. 114, no. 11, pp. 1376-1381.
Murray TG, O'Brien JM, Steeves RA, Smith BJ, Albert DM, Cicciarelli N et al. Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. Archives of Ophthalmology. 1996 Nov 1;114(11):1376-1381.
Murray, Timothy G. ; O'Brien, Joan M. ; Steeves, Richard A. ; Smith, Barbara J. ; Albert, Daniel M. ; Cicciarelli, Nicole ; Markoe, Arnold ; Tompkins, Dean T. ; Windle, Jolene J. / Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. In: Archives of Ophthalmology. 1996 ; Vol. 114, No. 11. pp. 1376-1381.
@article{0042bb7531b24023a217b994bf75e0d3,
title = "Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma",
abstract = "Background: Combined modality therapy for childhood retinoblastoma holds the potential of decreasing treatment related morbidity while maintaining excellent tumor control rates. Objective: To evaluate the efficacy of external beam radiation therapy (EBRT), ferromagnetic hyperthermia (FMH), and the combination of both modalities in the control of ocular tumors in a transgenic murine model of retinoblastoma. Methods: One hundred sixty-six mouse eyes from 4-week-old animals transgenically positive for simian virus 40 large T antigen were treated with a total dose of 10, 15, 20, 30, 40, 45, or 50 Gy of EBRT in 5-Gy fractions twice daily, with 48°C or 54°C FMH for 20 minutes, or with combined EBRT at 10 or 30 Gy and 48°C or 54°C FMH for 20 minutes. Serial histologic sections, obtained 8 weeks after treatment, were examined for the presence of tumor. Results: The tumor control dose for 50{\%} of eyes (TCD50) treated with EBRT occurred at 27.6 Gy. Ferromagnetic hyperthermia at 48°C cured 30{\%} (6/20) of eyes, while 54°C FMH resulted in a 100{\%} (20/20) cure rate. Combined treatment with 48°C FMH and EBRT exhibited a TCD50 at 3.3 Gy. The thermal enhancement ratio was 8.4. Ferromagnetic hyperthermia at 54°C exhibited tumor cure in all animals, but 25{\%} of eyes were lost owing to secondary treatment complications. Conclusions: This represents the first documentation of tumor control via EBRT, ocular FMH, and a combination of these treatment modalities in this murine transgenic retinoblastoma model. The extent of treatment synergy in this model suggests that combined treatment application may allow a reduction in total ocular and periocular radiation dose while maintaining excellent local tumor control.",
author = "Murray, {Timothy G.} and O'Brien, {Joan M.} and Steeves, {Richard A.} and Smith, {Barbara J.} and Albert, {Daniel M.} and Nicole Cicciarelli and Arnold Markoe and Tompkins, {Dean T.} and Windle, {Jolene J.}",
year = "1996",
month = "11",
day = "1",
language = "English",
volume = "114",
pages = "1376--1381",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma

AU - Murray, Timothy G.

AU - O'Brien, Joan M.

AU - Steeves, Richard A.

AU - Smith, Barbara J.

AU - Albert, Daniel M.

AU - Cicciarelli, Nicole

AU - Markoe, Arnold

AU - Tompkins, Dean T.

AU - Windle, Jolene J.

PY - 1996/11/1

Y1 - 1996/11/1

N2 - Background: Combined modality therapy for childhood retinoblastoma holds the potential of decreasing treatment related morbidity while maintaining excellent tumor control rates. Objective: To evaluate the efficacy of external beam radiation therapy (EBRT), ferromagnetic hyperthermia (FMH), and the combination of both modalities in the control of ocular tumors in a transgenic murine model of retinoblastoma. Methods: One hundred sixty-six mouse eyes from 4-week-old animals transgenically positive for simian virus 40 large T antigen were treated with a total dose of 10, 15, 20, 30, 40, 45, or 50 Gy of EBRT in 5-Gy fractions twice daily, with 48°C or 54°C FMH for 20 minutes, or with combined EBRT at 10 or 30 Gy and 48°C or 54°C FMH for 20 minutes. Serial histologic sections, obtained 8 weeks after treatment, were examined for the presence of tumor. Results: The tumor control dose for 50% of eyes (TCD50) treated with EBRT occurred at 27.6 Gy. Ferromagnetic hyperthermia at 48°C cured 30% (6/20) of eyes, while 54°C FMH resulted in a 100% (20/20) cure rate. Combined treatment with 48°C FMH and EBRT exhibited a TCD50 at 3.3 Gy. The thermal enhancement ratio was 8.4. Ferromagnetic hyperthermia at 54°C exhibited tumor cure in all animals, but 25% of eyes were lost owing to secondary treatment complications. Conclusions: This represents the first documentation of tumor control via EBRT, ocular FMH, and a combination of these treatment modalities in this murine transgenic retinoblastoma model. The extent of treatment synergy in this model suggests that combined treatment application may allow a reduction in total ocular and periocular radiation dose while maintaining excellent local tumor control.

AB - Background: Combined modality therapy for childhood retinoblastoma holds the potential of decreasing treatment related morbidity while maintaining excellent tumor control rates. Objective: To evaluate the efficacy of external beam radiation therapy (EBRT), ferromagnetic hyperthermia (FMH), and the combination of both modalities in the control of ocular tumors in a transgenic murine model of retinoblastoma. Methods: One hundred sixty-six mouse eyes from 4-week-old animals transgenically positive for simian virus 40 large T antigen were treated with a total dose of 10, 15, 20, 30, 40, 45, or 50 Gy of EBRT in 5-Gy fractions twice daily, with 48°C or 54°C FMH for 20 minutes, or with combined EBRT at 10 or 30 Gy and 48°C or 54°C FMH for 20 minutes. Serial histologic sections, obtained 8 weeks after treatment, were examined for the presence of tumor. Results: The tumor control dose for 50% of eyes (TCD50) treated with EBRT occurred at 27.6 Gy. Ferromagnetic hyperthermia at 48°C cured 30% (6/20) of eyes, while 54°C FMH resulted in a 100% (20/20) cure rate. Combined treatment with 48°C FMH and EBRT exhibited a TCD50 at 3.3 Gy. The thermal enhancement ratio was 8.4. Ferromagnetic hyperthermia at 54°C exhibited tumor cure in all animals, but 25% of eyes were lost owing to secondary treatment complications. Conclusions: This represents the first documentation of tumor control via EBRT, ocular FMH, and a combination of these treatment modalities in this murine transgenic retinoblastoma model. The extent of treatment synergy in this model suggests that combined treatment application may allow a reduction in total ocular and periocular radiation dose while maintaining excellent local tumor control.

UR - http://www.scopus.com/inward/record.url?scp=0029910955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029910955&partnerID=8YFLogxK

M3 - Article

C2 - 8906028

AN - SCOPUS:0029910955

VL - 114

SP - 1376

EP - 1381

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 11

ER -